Instructions for Azilect (Rasagiline)
Release form
Tablets
Description:
The tablets are white or almost white in color, round, flat-cylindrical, chamfered, engraved with "GIL 1" on one side of the tablet.
1 tab.
razagilina mezilat 1.56 mg,
This corresponds to the content of razagilin 1 mg
Auxiliary substances: mannitol - 159.24 mg, silicon dioxide colloidal - 1.2 mg, corn starch - 20 mg, corn starch pregelatinized - 20 mg, stearic acid - 4 mg, talc - 4 mg.
10 pcs - blister packs (3) - cardboard packs.
10 pcs - blister packs (10) - cardboard packs.
ATC codes
N04BD02 Rasagiline
Clinical-pharmacological groups / Group affiliation
Antiparkinsonian preparation - selective inhibitor of MAO type B
Active substance
razagilin
Pharmacotherapy group:
MAO inhibitor
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C.
Best before date
Shelf life is 3 years.
Testimony Azilect:
treatment of Parkinson's disease (in the form of monotherapy or combination therapy with levodopa preparations).
Method of use, course and dosage Azilect:
They are prescribed 1 mg once per day both as monotherapy and against the background of levodopa, for a long time.
The tablets are ingested regardless of the intake of food.
Overdose:
The overdose symptoms of Azilect are similar to those of non-selective MAO inhibitors (including arterial hypertension, postural hypotension).
Treatment: stomach flushing, activated carbon, symptomatic therapy. There is no specific antidote.
Contraindications for use Azilect:
hypersensitivity to razagilin or any of the components of the preparation;
simultaneous use with other MAO inhibitors (including medicinal preparations and dietary supplements containing hypericum powder), petidine. The interval between the withdrawal of razagilin and the commencement of therapy with these drugs should be at least 14 days;
Moderate to severe liver failure (grades B and C on the Child Pugh scale);
Children and adolescents under 18 years of age (no data on effectiveness and safety).
Careful
Mild liver failure (Child Pugh Class A);
simultaneous use with selective serotonin reuptake inhibitors (SSRIs) (including fluoxetine, fluvoxamine), selective serotonin and norepinephrine reuptake inhibitors (SSRIs), tricyclic and tetracyclic antidepressants, potent CYP1A2 isoenzyme inhibitors.
Use in liver disorders
It is contraindicated in moderate to severe liver failure (grade B and C on the Child Pugh scale).
Terms of Sale
The drug is prescription.
AZIL-RU-NP-00001-DOC-PHARM-19082016
Use in children
Contraindicated: Children and adolescents under 18 years of age.
Nosology (ICD codes)
G20
Parkinson's disease
G21
Secondary parkinsonism